Japan NHI Lists Pfizer’s Celsentri, Janssen’s Intelence for HIV
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare Jan. 16 posted for emergency national health coverage two HIV drugs - Pfizer's Celsentri (maraviroc) 150mg tablet and Janssen's Intelence (etravirine) 100mg tablet
You may also be interested in...
Novartis Gains Four New Drugs Under Japan NHI Reimbursement; Astellas, Takeda, BMS, GSK Make Gains
TOKYO - At the recommendation of the Central Social Insurance Medical Council, known as Chuikyo in Japanese, the Ministry of Health, Labor and Welfare has listed 11 new composites for national health insurance reimbursement coverage
Novartis Gains Four New Drugs Under Japan NHI Reimbursement; Astellas, Takeda, BMS, GSK Make Gains
TOKYO - At the recommendation of the Central Social Insurance Medical Council, known as Chuikyo in Japanese, the Ministry of Health, Labor and Welfare has listed 11 new composites for national health insurance reimbursement coverage
Japan To List Nine Composites For National Health Insurance Coverage
TOKYO - At its Dec. 3 plenary meeting, Chuikyo (the Central Social Insurance and Medical Council), the government-private body that sets Japan's medical and pharmaceutical policies, approved the listing of nine composites for 13 pharmaceutical products, including the relisting of Fujimoto's Thaled (thalidomide) for multiple myeloma